ebronucimab

Home
Ligands
ebronucimab

GtoPdb Ligand ID: 13786

Synonyms: AK-102 | AK102 | inusimab

ebronucimab is an approved drug

Comment: Ebronucimab (AK-102) is a subcutaneous fully human anti-proprotein convertase subtilisin/kexin type 9 (PCSK9) monoclonal antibody. It blocks binding between circulating PCSK9 and the LDL receptor on hepatocytes. This reduces LDL receptor degradation, thus increasing the number of LDL receptors on cells, and effectively increasing hepatic removal LDL cholesterol from the circulation. Ebronucimab was developed for patients at high risk for cardiovascular disease when lipid-lowering cannot be achieved with statins or statins + ezetimibe.

References
1. Blair HA. (2025) Ebronucimab: First Approval. Drugs, 85 (3): 437-441. [PMID:39913020]
2. Zhang Y, Pei Z, Chen B, Qu Y, Dong X, Yu B, Wang G, Xu F, Lu D, He Z et al.. (2024) Ebronucimab in Chinese patients with hypercholesterolemia---A randomized double-blind placebo-controlled phase 3 trial to evaluate the efficacy and safety of ebronucimab. Pharmacol Res, 207: 107340. [PMID:39111557]

References

1. Blair HA. (2025)
Ebronucimab: First Approval.
Drugs, 85 (3): 437-441. [PMID:39913020]

2. Zhang Y, Pei Z, Chen B, Qu Y, Dong X, Yu B, Wang G, Xu F, Lu D, He Z et al.. (2024)
Ebronucimab in Chinese patients with hypercholesterolemia---A randomized double-blind placebo-controlled phase 3 trial to evaluate the efficacy and safety of ebronucimab.
Pharmacol Res, 207: 107340. [PMID:39111557]